Menu

Publications

Complete list here 👉🏻 https://bit.ly/2Uu64Xs

* indicates co-first authorship; # indicates corresponding authorship; Δ to indicate a brief description of significance (for 10 selected articles).

  • Air Pollution Particulate Matter Exposure and Chronic Cerebral Hypoperfusion and Measures of White Matter Injury in a Murine Model. Environ Health Perspect. 2021 Aug; 129(8):87006. Liu Q, Shkirkova K, Lamorie-Foote K, Connor M, Patel A, Babadjouni R, Huuskonen M, Montagne A, Baertsch H, Zhang H, Chen JC, Mack WJ, Walcott BP, Zlokovic BV, Sioutas C, Morgan TE, Finch CE, Mack WJ. PMID: 34424052.
  • Magnetic Resonance Imaging of Blood-Brain Barrier Permeability in Dementia. Neuroscience. 2021 Aug 13; S0306-4522(21)00402-4 (in press). Chagnot A, Barnes SR, Montagne A#. PMID: 34400249.
  • Interplay between brain pericytes and endothelial cells in dementia. Am J Pathol. 2021 Jul 27; S0002-9440(21)00340-0 (in press). Procter T, Williams A, Montagne A#. PMID: 34329605.
  • APOE4 accelerates advanced stage vascular and neurodegenerative disorder in old Alzheimer’s mice via cyclophilin A independently of amyloid-β. Nature Aging. 2021; 1:506–520.  Montagne A, Nikolakopoulou AM, Huuskonen MT, Sagare AP, Lawson EJ, Lazic D, Rege SV, Grond A, Zuniga E, Barnes SR, Prince J, Sagare M, Hsu CJ, LaDu MJ, Jacobs RE, Zlokovic BV.
  • Alzheimer’s Pathogenic Mechanisms and underlying Sex Difference. Cell Mol Life Sci. 2021 Jun; 78(11):4907-4920. Zhu D, Montagne A, Zhao Z. PMID: 33844047.
  • Evidence that blood-CSF barrier transport, but not inflammatory biomarkers, change in migraine, while CSF sVCAM1 associates with migraine frequency and CSF fibrinogen. Headache. 2021 Mar; 61(3):536-545. Cowan RP, Gross NB, Sweeney MD, Sagare AP, Montagne A, Arakaki X, Fonteh AN, Zlokovic BV, Pogoda JM, Harrington MG. PMID: 33724462.
  • Endothelial LRP1 maintains the blood-brain barrier and neuronal function via cyclophilin A. J Exp Med. 2021 Apr 5; 218(4):e20202207. Nikolakopoulou AM, Wang Y, Ma Q, Sagare AP, Montagne A, Huuskonen MT, Rege SV, Dai Z, Kisler K, Körbelin J, Herz J, Zhao Z, Zlokovic BV. PMID: 33533918.
  • New mechanistic insights, novel treatment paradigms, and clinical progress in cerebrovascular diseases. Front Aging Neurosci. 2021 Jan 28; 13:623751. Boltze J, Aronoswski JA, Badaut J, Buckwalter MS, Caleo M, Chopp M, Dave KR, Didwischus N, Dijkhuizen RM, Doeppner TR, Dreier JP, Fouad K, Gelderblom M, Gertz K, GoĹ‚ubczyk D, Gregson B, Hamel E, Hanley D, Härtig W, Hummel FC, Ikhsan M, Janowski M, Jolkkonen J, Karuppagounder SS, Keep RF, Koerte IK, Kokaia Z, Li P, Liu F, Lizasoain I, Ludewig P, Metz G, Montagne A, Obenaus A, Palumbo A, Pearl M, Perez-Pinzon M, Planas AM, Plesnila N, Popa-Wagner A, Raval AP, Rueger MA, Sansing LH, Sohrabji F, Stagg CJ, Stetler RA, Stowe A, Sun D, Taguchi A, Tanter M, Vay SU, Vemuganti R, Vivien D, Walczak P, Wang J, Xiong Y, Zille M.
  • Cranial Suture Regeneration Mitigates Skull and Neurocognitive Defects in Craniosynostosis. Cell. 2021 Jan 7; 184(1):243-256.e18. Yu M, Ma L, Yuan Y, Ye X, Montagne A, He J, Ho TV, Wu Y, Zhao Z, Sta Maria N, Jacobs R, Urata M, Wang H, Zlokovic BV, Chen JF, Chai Y. PMID: 33417861.
  • A Review of Translational Magnetic Resonance Imaging in Human and Rodent Experimental Models of Small Vessel Disease. Transl Stroke Res. 2021 Feb; 12(1):15-30. Stringer MS, Lee H, Huuskonen MT, MacIntosh BJ, Brown R, Montagne A, Atwi S, Ramirez J, Jansen MA, Marshall I, Black SE, Zlokovic BV, Benveniste H, Wardlaw JM. PMID: 32936435.
  • Comparison Between Blood-Brain Barrier Water Exchange Rate and Permeability to Gadolinium-Based Contrast Agent in an Elderly Cohort. Front Neurosci. 2020 Nov 30; 14:571480. Shao X, Jann K, Ma SJ, Yan L, Montagne A, Ringman JM, Zlokovic BV, Wang DJJ. PMID: 33328848.
  • APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature. 2020 05; 581(7806):71-76. Montagne A, Nation DA, Sagare AP, Barisano G, Sweeney MD, Chakhoyan A, Pachicano M, Joe E, Nelson AR, D’Orazio LM, Buennagel DP, Harrington MG, Benzinger TLS, Fagan AM, Ringman JM, Schneider LS, Morris JC, Reiman EM, Caselli RJ, Chui HC, Tcw J, Chen Y, Pa J, Conti PS, Law M, Toga AW, Zlokovic BV. PMID: 32376954.

ΔThe gene variant APOE4 is linked to defects in the blood–brain barrier via activation of cyclophilin A and matrix metalloproteinase-9 in pericytes, ultimately causing vascular disruption in brain regions involved in learning and memory.

  • A novel sensitive assay for detection of a biomarker of pericyte injury in cerebrospinal fluid. Alzheimers Dement. 2020 Jun; 16(6):821-830. Sweeney MD, Sagare AP, Pachicano M, Harrington MG, Joe E, Chui HC, Schneider LS, Montagne A, Ringman JM, Fagan AM, Morris JC, Pa J, Nation DA, Toga AW, Zlokovic BV. PMID: 32301266.
  • Perivascular spaces in the brain: anatomy, physiology and pathology. Nat Rev Neurol. 2020 03; 16(3):137-153. Wardlaw JM, Benveniste H, Nedergaard M, Zlokovic BV, Mestre H, Lee H, Doubal FN, Brown R, Ramirez J, MacIntosh BJ, Tannenbaum A, Ballerini L, Rungta RL, Boido D, Sweeney M, Montagne A, Charpak S, Joutel A, Smith KJ, Black SE. PMID: 32094487.
  • APOE4 Accelerates Development of Dementia After Stroke: Is There a Role for Cerebrovascular Dysfunction? Stroke. 2020 03; 51(3):699-700. Montagne A, Nation DA, Zlokovic BV. PMID: 32070225.
  • Proceedings from the Albert Charitable Trust Inaugural Workshop on white matter and cognition in aging. Geroscience. 2020 02; 42(1):81-96. Sorond FA, Whitehead S, Arai K, Arnold D, Carmichael ST, De Carli C, Duering M, Fornage M, Flores-Obando RE, Graff-Radford J, Hamel E, Hess DC, Ihara M, Jensen MK, Markus HS, Montagne A, Rosenberg G, Shih AY, Smith EE, Thiel A, Tse KH, Wilcock D, Barone F. PMID: 31811528.
  • Undetectable gadolinium brain retention in individuals with an age-dependent blood-brain barrier breakdown in the hippocampus and mild cognitive impairment. Alzheimers Dement. 2019 12; 15(12):1568-1575. Montagne A, Huuskonen MT, Rajagopal G, Sweeney MD, Nation DA, Sepehrband F, D’Orazio LM, Harrington MG, Chui HC, Law M, Toga AW, Zlokovic BV. PMID: 31862169.

ΔGadolinium MRI contrast agents do not accumulate in brains of individuals with age-dependent blood-brain barrier breakdown in the hippocampus and mild cognitive impairment as shown at 2 years after administration.

  • Pericyte loss leads to circulatory failure and pleiotrophin depletion causing neuron loss. Nat Neurosci. 2019 07; 22(7):1089-1098. Nikolakopoulou AM, Montagne A*, Kisler K, Dai Z, Wang Y, Huuskonen MT, Sagare AP, Lazic D, Sweeney MD, Kong P, Wang M, Owens NC, Lawson EJ, Xie X, Zhao Z, Zlokovic BV. PMID: 31235908.

ΔBrain capillary disruption leads to rapid circulatory failure and neuronal loss via the loss of a specific capillary growth factor called pleiotrophin (PTN). Restoring PTN levels prevented neuron loss and behaviour deficits in mice with vascular defects.

  • Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019 02; 25(2):270-276. Nation DA, Sweeney MD, Montagne A*, Sagare AP, D’Orazio LM, Pachicano M, Sepehrband F, Nelson AR, Buennagel DP, Harrington MG, Benzinger TLS, Fagan AM, Ringman JM, Schneider LS, Morris JC, Chui HC, Law M, Toga AW, Zlokovic BV. PMID: 30643288.

ΔAs shown with our novel pericyte injury biomarker (sPDGFRβ) combined with neuroimaging, an accelerated vascular breakdown may contribute to cognitive impairment, independently of the classical Alzheimer’s amyloid and tau biomarkers.

  • Blood-Brain Barrier: From Physiology to Disease and Back. Physiol Rev. 2019 01 01; 99(1):21-78. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. PMID: 30280653.
  • Vascular dysfunction-The disregarded partner of Alzheimer’s disease. Alzheimers Dement. 2019 01; 15(1):158-167. Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, Harrington MG, Pa J, Law M, Wang DJJ, Jacobs RE, Doubal FN, Ramirez J, Black SE, Nedergaard M, Benveniste H, Dichgans M, Iadecola C, Love S, Bath PM, Markus HS, Salman RA, Allan SM, Quinn TJ, Kalaria RN, Werring DJ, Carare RO, Touyz RM, Williams SCR, Moskowitz MA, Katusic ZS, Lutz SE, Lazarov O, Minshall RD, Rehman J, Davis TP, Wellington CL, González HM, Yuan C, Lockhart SN, Hughes TM, Chen CLH, Sachdev P, O’Brien JT, Skoog I, Pantoni L, Gustafson DR, Biessels GJ, Wallin A, Smith EE, Mok V, Wong A, Passmore P, Barkof F, Muller M, Breteler MMB, Román GC, Hamel E, Seshadri S, Gottesman RF, van Buchem MA, Arvanitakis Z, Schneider JA, Drewes LR, Hachinski V, Finch CE, Toga AW, Wardlaw JM, Zlokovic BV. PMID: 30642436.
  • The role of brain vasculature in neurodegenerative disorders. Nat Neurosci. 2018 10; 21(10):1318-1331. Sweeney MD, Kisler K, Montagne A*, Toga AW, Zlokovic BV. PMID: 30250261.
  • Permeability imaging as a predictor of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2018 06; 38(6):973-979. Russin JJ, Montagne A*, D’Amore F, He S, Shiroishi MS, Rennert RC, Depetris J, Zlokovic BV, Mack WJ. PMID: 29611451.
  • Pericyte degeneration causes white matter dysfunction in the mouse central nervous system. Nat Med. 2018 03; 24(3):326-337. Montagne A, Nikolakopoulou AM, Zhao Z, Sagare AP, Si G, Lazic D, Barnes SR, Daianu M, Ramanathan A, Go A, Lawson EJ, Wang Y, Mack WJ, Thompson PM, Schneider JA, Varkey J, Langen R, Mullins E, Jacobs RE, Zlokovic BV. PMID: 29400711.

ΔBrain capillary breakdown initiates white matter dysfunction, which can be reversed by limiting fibrinogen extravascular deposits. It has implications for the pathogenesis and treatment of human WM disease associated with AD.

  • Alzheimer’s disease: A matter of blood-brain barrier dysfunction? J Exp Med. 2017 Nov 06; 214(11):3151-3169. Montagne A, Zhao Z, Zlokovic BV. PMID: 29061693.

ΔLiterature review which summarizes all pre-clinical and clinical evidence supporting the contribution of early vascular dysfunctions to Alzheimer’s disease. Importantly, the potential pitfalls in blood-brain barrier (BBB) permeability measurements and new therapies for BBB repair to control neurodegeneration are also discussed.

  • Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017 07; 18(7):419-434. Kisler K, Nelson AR, Montagne A*, Zlokovic BV. PMID: 28515434.
  • Regional early and progressive loss of brain pericytes but not vascular smooth muscle cells in adult mice with disrupted platelet-derived growth factor receptor-Ăź signaling. PLoS One. 2017; 12(4):e0176225. Nikolakopoulou AM, Zhao Z, Montagne A, Zlokovic BV. PMID: 28441414.
  • Brain imaging of neurovascular dysfunction in Alzheimer’s disease. Acta Neuropathol. 2016 May; 131(5):687-707. Montagne A, Nation DA, Pa J, Sweeney MD, Toga AW, Zlokovic BV. PMID: 27038189.
  • Blood-Brain Barrier Permeability and Gadolinium: Benefits and Potential Pitfalls in Research. JAMA Neurol. 2016 Jan; 73(1):13-4. Montagne A, Toga AW, Zlokovic BV. PMID: 26524294.
  • Tissue Plasminogen Activator Expression Is Restricted to Subsets of Excitatory Pyramidal Glutamatergic Neurons. Mol Neurobiol. 2016 09; 53(7):5000-12. Louessard M, Lacroix A, Martineau M, Mondielli G, Montagne A, Lesept F, Lambolez B, Cauli B, Mothet JP, Vivien D, Maubert E. PMID: 26377106.
  • ROCKETSHIP: a flexible and modular software tool for the planning, processing and analysis of dynamic MRI studies. BMC Med Imaging. 2015 Jun 16; 15:19. Barnes SR, Ng TS, Santa-Maria N, Montagne A, Zlokovic BV, Jacobs RE. PMID: 26076957.
  • Optimal acquisition and modeling parameters for accurate assessment of low Ktrans blood-brain barrier permeability using dynamic contrast-enhanced MRI. Magn Reson Med. 2016 May; 75(5):1967-77. Barnes SR, Ng TS, Montagne A, Law M, Zlokovic BV, Jacobs RE. PMID: 26077645.
  • Vascular plasticity and cognition during normal aging and dementia. JAMA Neurol. 2015 May; 72(5):495-6. Montagne A, Pa J, Zlokovic BV. PMID: 25751405.
  • Impact of alcohol consumption on the outcome of ischemic stroke and thrombolysis: role of the hepatic clearance of tissue-type plasminogen activator. Stroke. 2015 Jun; 46(6):1641-50. Lemarchand E, Gauberti M, Martinez de Lizarrondo S, Villain H, RepessĂ© Y, Montagne A, Vivien D, Ali C, Rubio M. PMID: 25922513.
  • 7T Multi-shell Hybrid Diffusion Imaging (HYDI) for Mapping Brain Connectivity in Mice. Proc SPIE Int Soc Opt Eng. 2015 Mar 20; 9413. Daianu M, Jahanshad N, Villalon-Reina JE, Prasad G, Jacobs RE, Barnes S, Zlokovic BV, Montagne A, Thompson PM. PMID: 25859293.
  • Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015 Jan 21; 85(2):296-302. Montagne A, Barnes SR, Sweeney MD, Halliday MR, Sagare AP, Zhao Z, Toga AW, Jacobs RE, Liu CY, Amezcua L, Harrington MG, Chui HC, Law M, Zlokovic BV. PMID: 25611508.

ΔThe blood-brain barrier (BBB) breaks down in the hippocampus, a region critical for learning and memory, during normal aging. It worsens with mild cognitive impairment and correlates with injury to BBB-associated pericytes.

  • Molecular magnetic resonance imaging of brain-immune interactions. Front Cell Neurosci. 2014; 8:389. Gauberti M, Montagne A, Quenault A, Vivien D. PMID: 25505871.
  • Urokinase versus Alteplase for intraventricular hemorrhage fibrinolysis. Neuropharmacology. 2014 Oct; 85:158-65. Gaberel T, Montagne A*, Lesept F, Gauberti M, Lemarchand E, Orset C, Goulay R, Bertrand T, Emery E, Vivien D. PMID: 24846802.
  • GpIba-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice. Blood. 2014 May 22; 123(21):3354-63. Le Behot A, Gauberti M, Martinez De Lizarrondo S, Montagne A, Lemarchand E, Repesse Y, Guillou S, Denis CV, Maubert E, Orset C, Vivien D. PMID: 24553181.
  • Intracerebral hematomas disappear on T2*-weighted images during normobaric oxygen therapy. Stroke. 2013 Dec; 44(12):3482-9. Gaberel T, Gakuba C, Hebert M, Montagne A, Agin V, Rubio M, Emery E, Vivien D, Gauberti M. PMID: 24105700.
  • Ultra-sensitive molecular MRI of vascular cell adhesion molecule-1 reveals a dynamic inflammatory penumbra after strokes. Stroke. 2013 Jul; 44(7):1988-96. Gauberti M, Montagne A*, Marcos-Contreras OA, Le BĂ©hot A, Maubert E, Vivien D. PMID: 23743972.

ΔMolecular MRI targeting cerebrovascular inflammation after stroke suggests the presence of an inflammatory penumbra which could constitute an imaging criterion to select patients for subacute anti-inflammatory treatments.

  • Immunotherapy blocking the tissue plasminogen activator-dependent activation of N-methyl-D-aspartate glutamate receptors improves hemorrhagic stroke outcome. Neuropharmacology. 2013 Apr; 67:267-71. Gaberel T, Macrez R, Gauberti M, Montagne A, Hebert M, Petersen KU, Touze E, Agin V, Emery E, Ali C, Vivien D. PMID: 23219658.
  • Memantine improves safety of thrombolysis for stroke. Stroke. 2012 Oct; 43(10):2774-81. Montagne A, HĂ©bert M, Jullienne A, Lesept F, Le BĂ©hot A, Louessard M, Gauberti M, Orset C, Ali C, Agin V, Maubert E, Vivien D. PMID: 22879098.

ΔThe Alzheimer’s drug Memantine could be used as an adjunct therapy to improve the safety of rtPA-induced thrombolysis. Remarkably, memantine also rescues rtPA-induced hematoma expansion and survival rate.

  • Ultra-sensitive molecular MRI of cerebrovascular cell activation enables early detection of chronic central nervous system disorders. Neuroimage. 2012 Nov 01; 63(2):760-70. Montagne A, Gauberti M, Macrez R, Jullienne A, Briens A, Raynaud JS, Louin G, Buisson A, Haelewyn B, Docagne F, Defer G, Vivien D, Maubert E. PMID: 22813950.

ΔA novel MRI contrast agent allows ultra-sensitive assessment of cerebrovascular activation. Diagnosis and non-invasive evaluation of brain disorders appear to be feasible even before symptom appearance.

  • Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity. Cell Death Differ. 2012 Dec; 19(12):1983-91. Parcq J, Bertrand T, Montagne A, Baron AF, Macrez R, Billard JM, Briens A, Hommet Y, Wu J, Yepes M, Lijnen HR, Dutar P, AnglĂ©s-Cano E, Vivien D. PMID: 22743997.
  • Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals. J Neurosci. 2012 Apr 11; 32(15):5186-99. CassĂ© F, Bardou I, Danglot L, Briens A, Montagne A, Parcq J, Alahari A, Galli T, Vivien D, Docagne F. PMID: 22496564.
  • Selective inhibition of GluN2D-containing N-methyl-D-aspartate receptors prevents tissue plasminogen activator-promoted neurotoxicity both in vitro and in vivo. Mol Neurodegener. 2011 Oct 05; 6:68. Jullienne A, Montagne A*, Orset C, Lesept F, Jane DE, Monaghan DT, Maubert E, Vivien D, Ali C. PMID: 21975018.
  • Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J Cereb Blood Flow Metab. 2011 Nov; 31(11):2119-34. Vivien D, Gauberti M, Montagne A, Defer G, TouzĂ© E. PMID: 21878948.
  • Tissue plasminogen activator prevents white matter damage following stroke. J Exp Med. 2011 Jun 06; 208(6):1229-42. Correa F, Gauberti M, Parcq J, Macrez R, Hommet Y, Obiang P, HernangĂłmez M, Montagne A, Liot G, Guaza C, Maubert E, Ali C, Vivien D, Docagne F. PMID: 21576385.
  • NR2D-containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotoxicity. Cell Death Differ. 2010 May; 17(5):860-71. Baron A, Montagne A, CassĂ© F, Launay S, Maubert E, Ali C, Vivien D. PMID: 19911010.